U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

You may have been too young to remember, but depending on your state’s school immunization requirements, you likely received ...

RSV rates can be expected to increase, and flu, as well as other common viruses. Human metapneumovirus tends to peak in ...

Despite the Centers for Disease Control and Prevention's recommendations, vaccine rates against COVID-19, RSV, and the flu ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.

In addition to vaccinations, Shah emphasizes the importance of avoiding gatherings when you do not feel well and shares an ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...